Business Relations Table - o4.fyi ()

Anmelden Gast|Guest
Beispiel: brt.php?search=wide&s=wide&p=adjective&o=wideness

Domain-Statistiken für "avttx.com"

57
Business Relations
57
Eindeutige Domains
20
Gefundene Einträge
BR-Relations: 57
From Domain Role To Domain Path Aktionen
/portfolio
/february-2025-venture-growth-funding-recap/
/marketnovel-tech/ashvattha-therapeutics-has-announced-positive-phase-2-results-for-subcutaneous-migaldendranib-delivered-via-a-hydroxyl-dendrimer-for-retinal-vascular-disease
/ashvattha-unveils-transformative-dendrimer-based-anti-vegf-treatment-for-retinal-diseases/
/ashvattha-therapeutics-subsidiary-orpheris-announces-fda-agreement-to-initiate-phase-2-study-evaluating-op-101-in-severe-covid-19-patients/
/ashvattha-therapeutics-presents-preclinical-data-at-the-american-society-of-nephrology-asn-virtual-kidney-week-2020/
/ashvattha-therapeutics-selected-to-present-virtual-poster-at-acr-convergence-2020/
/2020/11/
/ashvattha-therapeutics-to-present-at-2021-sachs-7th-annual-digital-immuno-oncology-innovation-forum/
/ashvattha-therapeutics-to-present-at-2021-sachs-7th-annual-digital-immuno-oncology-innovation-forum/
/ashvattha-therapeutics-announces-participation-at-upcoming-investor-conferences/
/ashvattha-therapeutics-announces-participation-at-upcoming-investor-conferences/
/ashvattha-therapeutics-announces-participation-at-upcoming-investor-conferences/
/ashvattha-therapeutics-presents-phase-1-safety-data-in-healthy-subjects-for-subcutaneous-anti-vegf-wet-amd-and-dme-candidate-at-the-association-for-research-in-vision-and-ophthalmology-arvo-2022-ann/
/ashvattha-therapeutics-announces-publication-of-data-in-science-translational-medicine-from-phase-2a-clinical-trial-for-op-101-in-severe-covid-19-showing-significant-reduction-in-inflammatory-and-neur/
/ashvattha-therapeutics-to-present-at-biotech-showcase-2023/
/ashvattha-therapeutics-to-present-at-upcoming-investor-conferences/
/ashvattha-therapeutics-to-present-at-upcoming-investor-conferences/
/ashvattha-therapeutics-announces-first-patient-enrolled-in-a-phase-1-study-of-18fop-801-for-use-as-imaging-agent/
/ashvattha-therapeutics-announces-first-patient-enrolled-in-a-phase-1-study-of-18fop-801-for-use-as-imaging-agent/